Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer

Journal of Surgical Oncology

Volumn 102, Issue 8, 2010, Pages 955-959

  Strasberg, Steven M ^a   Dehdashti, Farrokh ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

colorectal metastases; heaptic metastases; surgical resection

Indexed keywords

FLUORODEOXYGLUCOSE;

CANCER STAGING; COLORECTAL CANCER; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; LIVER METASTASIS; LIVER RESECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 78650652366     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21729     Document Type: Review

References (43)

1. Small RM, Lubezky N, Shmueli E, et al.: Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol 2009; 99: 93-98.
2. Akhurst T, Kates TJ, Mazumdar M, et al.: Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005; 23: 8713-8716.
3. Truant S, Huglo D, Hebbar M, et al.: Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 2005; 92: 362-369.
4. Bipat S, van Leeuwen MS, Comans EF, et al.: Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 2005; 237: 123-131.
5. Kinkel K, Lu Y, Both M, et al.: Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis. Radiology 2002; 224: 748-756.
6. Huebner RH, Park KC, Shepherd JE, et al.: A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41: 1177-1189.
7. Wiering B, Krabbe PF, Jager GJ, et al.: The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005; 104: 2658-2670.
8. Orlacchio A, Schillaci O, Fusco N, et al.: Role of PET/CT in the detection of liver metastases from colorectal cancer. Radiol Med 2009; 114: 571-585.
9. Kong G, Jackson C, Koh DM, et al.: The use of 18F-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008; 35: 1323-1329.
10. Rappeport ED, Loft A, Berthelsen AK, et al.: Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: A prospective study with intraoperative confirmation. Acta Radiol 2007; 48: 369-378.
11. Cantwell CP, Setty BN, Holalkere N, et al.: Liver lesion detection and characterization in patients with colorectal cancer: A comparison of low radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI. J Comput Assist Tomogr 2008; 32: 738-744.
12. Coenegrachts K, De Geeter F, ter Beek L, et al.: Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases. Eur Radiol 2009; 19: 370-379.
13. Yang YY, Fleshman JW, Strasberg SM, et al.: Detection and management of extrahepatic colorectal cancer in patients with resectable liver metastases. J Gastrointest Surg 2007; 11: 929-944.
14. Fong Y, Saldinger PF, Akhurst T, et al.: Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999; 178: 282-287.
15. Lai DT, Fulham M, Stephen MS, et al.: The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996; 131: 703-707.
16. Strasberg SM, Dehdashti F, Siegel BA, et al.: Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: A prospective database study [see comment]. Ann Surg 2001; 233: 293-299.
17. Schussler-Fiorenza CM, Mahvi DM, Niederhuber J, et al.: Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases. J Gastrointest Surg 2004; 8: 150-157.
18. Rosa F, Meimarakis G, Stahl A, et al.: Colorectal cancer patients before resection of hepatic metastases. Impact of (18)F-FDG PET on detecting extrahepatic disease. Nucl Med 2004; 43: 135-140.
19. Ruers TJ, Langenhoff BS, Neeleman N, et al.: Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study. J Clin Oncol 2002; 20: 388-395.
20. Zhuang H, Sinha P, Pourdehnad M, et al.: The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun 2000; 21: 793-798.
21. Vitola JV, Delbeke D, Meranze SG, et al.: Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer 1996; 78: 2216-2222.
22. Arulampalam TH, Francis DL, Visvikis D, et al.: FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol 2004; 30: 286-291.
23. Selzner M, Hany TF, Wildbrett P, et al.: Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004; 240: 1027-1034.
24. Adam R, de Haas RJ, Wicherts DA, et al.: Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol 3672; 26: 3672-3680.
25. Verwaal VJ, van Ruth S, de Bree E, et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743.
26. Verwaal VJ, van Ruth S, Witkamp A, et al.: Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12: 65-71.
27. Fernandez FG, Ritter J, Goodwin JW, et al.: Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 845-853.
28. Rubbia-Brandt L, Audard V, Sartoretti P, et al.: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-466.
29. de Geus-Oei LF, Vriens D, van Laarhoven HW, et al.: Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: A systematic review. J Nucl Med 2009; 50: 43S-54S.
30. Tan MC, Linehan DC, Hawkins WG, et al.: Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007; 11: 1112-1119.
31. Goshen E, Davidson T, Zwas ST, et al.: PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat 2006; 5: 37-43.
32. Angliviel B, Benoist S, Penna C, et al.: Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases. Ann Surg Oncol 1247; 16: 1247-1253.
33. Pawlik TM, Assumpcao L, Vossen JA, et al.: Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases timothy. Ann Surg Oncol 2009; 16: 371-378.
34. Ruers TJM, Wiering B, van der Sijp JRM, et al.: Improved selection of patients for hepaticsurgery of colorectal liver metastases with 18F-FDG PET: A randomized study. J Nucl Med 2009; 50: 1036-1041.
35. Fernandez FG, Drebin JA, Linehan DC, et al.: Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240: 438-447.
36. Finkelstein SE, Fernandez FG, Dehdashti F, et al.: Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET. J HPB Surg 2008; 15: 483-487.
37. Tan MC, Castaldo ET, Gao F, et al.: A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: Role of primary tumor variables. J Am Coll Surg 2008; 206: 857-868.
38. Gearhart SL, Frassica D, Rosen R, et al.: Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol 2006; 13: 397-404.
39. Libutti SK, Alexander HR, Jr., Choyke P, et al.: A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels [see comment]. Ann Surg Oncol 2001; 8: 779-786.
40. Zervos EE, Badgwell BD, Burak WE, Jr., et al.: Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery 2001; 130: 636-643; discussion 43-44.
41. Flamen P, Hoekstra OS, Homans F, et al.: Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: The utility of positron emission tomography (PET). Eur J Cancer 2001; 37: 862-869.
42. Flanagan FL, Dehdashti F, Ogunbiyi OA, et al.: Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer [see comment]. Ann Surg 1998; 227: 319-323.
43. Liu FY, Chen JS, Changchien CR, et al.: Utility of 2-fluoro-2-deoxy-D- glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels. Dis Col Rect 2005; 48: 1900-1912.